|  | | Company Overview | | |  | | | For Investors
The information on this site is intended only for investors. All visitors should read the important advisory information by clicking here.
Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. Schering-Plough is a publicly traded company with shares listed on the New York Stock Exchange (ticker symbol SGP).
 |
| Date | Title | | 08/19/08 | Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11| ASMANEX is the first and only once-daily inhaled corticosteroid inhaler
approved for children as young as age 4
KENILWORTH, N.J., Aug. 19 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) announced today that ASMANEX(R) TWISTHALER(R) 110 mcg
(mometasone furoate inhalation powder) is now available in pharmacies
nationwide. ASMANEX is indicated for the maintenance treatment of asthma as
prophylactic therapy in patients four years of age and older, a... |
| | 08/12/08 | Schering-Plough Expands Its Presence in China, Enters Next Stage of Development| KENILWORTH, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) today announced that it has expanded its presence in
China and established Shanghai Schering-Plough Pharmaceutical Co. Ltd., as a
wholly owned operation based in Shanghai through the acquisition of the shares
of its former joint venture partners.
"The actions announced today are part of Schering-Plough's long-term
global geographic expansion strategy," said Fred Hassan, chairman and chief
e... |
| | 08/05/08 | World Champion Gymnast Shannon Miller Forms Winning Partnership with Non-Drowsy Claritin(R)| Miller reveals how managing her allergy symptoms helps her achieve her
current peak performance
KENILWORTH, N.J., Aug. 5 /PRNewswire-FirstCall/ -- As host city of the
2008 Summer Olympic Games, Beijing will introduce thousands of spectators and
athletes from around the world to an array of new customs and sights, but many
of these visitors may also experience allergy symptoms like sneezing and
itchy, watery eyes as they explore this new environment. Shannon Miller,
America's most ... |
| | 08/04/08 | Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients|
74 percent of patients achieved SVR 12 with 48-week boceprevir-based
combination therapy
High SVR 24 rate also reported for 28-week boceprevir arm
KENILWORTH, N.J., Aug. 4 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) today reported top-line results from a planned interim
analysis of a Phase II study of boceprevir, its investigational oral hepatitis
C protease inhibitor. The analysis showed a high rate of sust... |
|
|
|
For Investor inquiries call 908-298-7436 
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |
| | |
|
Receive E-mail Alerts | Alerts are e-mailed to you whenever certain new company information is posted to this site.
Sign-up Now! |
|
About Us
